Why Invest

Fact Sheet


Click here for Immunovaccine's Fact Sheet

Immunovaccine Inc. (TSX-V: IMV) is a clinical stage vaccine development company focused on the commercialization of its patented DepoVax™ vaccine delivery platform and product candidates.

With a goal of developing premium vaccines the company is strengthening its pipeline through licensing and strategic partnering.

Immunovaccine is well positioned for growth by having: 

  • Two therapeutic cancer vaccines; DPX-0907 and DPX-Survivac, progressing quickly through the clinical trial process and showing positive results
  • Broadly tested DepoVax platform capable of enhancing a range of infectious disease and therapeutic cancer vaccines
  • Proprietary commercial scale vaccine manufacturing capability
  • Strong IP position with patents issued in the US, EU and Asia
  • Out-licensing agreements signed with Pfizer Inc. for new livestock vaccines

The value of the DepoVax platform continues to grow with positive clinical safety data. Immunovaccine’s management team is also leveraging the potential of DepoVax by securing partnerships with NCI, National Research Council Canada, Defense Research & Development Canada, Vaxil Therapeutics, Oncothyreon, IRX Therapeutics, Oncotherapy Science and CIMAB SA.

Click Here to visit Immunovaccine's Document Library. The Document Library (www.deliveringbreakthroughs.com)  is available to all current and potential investors and partners